Lipoprotein-associated phospholipase A2: A New Therapeutic Target

Canadian Journal of Cardiology

Volumn 26, Issue SUPPLA, 2010, Pages 27A-31A

  Lonn, Eva ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Inflammation; Plaque rupture

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; DARAPLADIB; PLACEBO; RILAPLADIB; BENZALDEHYDE DERIVATIVE; OXIME;

APOPTOSIS; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIMARY PREVENTION; STROKE; TREATMENT DURATION; DRUG EFFECT; ENZYMOLOGY; METABOLISM; REVIEW; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BENZALDEHYDES; CORONARY ARTERY DISEASE; HUMANS; OXIMES; RISK FACTORS;

EID: 77952758751     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)71058-8     Document Type: Article

References (46)

1. World Health Statistics 2009. Table 2. Cause-specific mortality and morbidity. (Accessed on August 5, 2009).
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
3. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med 2003;139:670-82.
4. Stafforini DM, Prescott SM, McIntyre TM. Human plasma plateletactivating factor acetylhydrolase. Purification and properties. J Bio Chem 1987;262:4223-30.
5. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of lowdensity lipoprotein: Use of a novel inhibitor. Biochem J 1999;338:479-87.
6. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002;3:57-68.
7. 2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-31.
8. 2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2008;26:2523-9.
9. 2 andoxidized low-density lipoprotein in carotid atherosclerosis. J Lipid Res 2009;50:1735-43.
10. 2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059-66.
11. 2 and lysophosphatidylcholine in the coronary circulation: Association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715-21.
12. 2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006;26:106-11.
13. 2: An independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008;101(Suppl):23F-33F.
14. 2 and risk of stroke. Am J Cardiol 2008;101(Suppl):34F-40F.
15. 2 as an independent predictor of coronary heart disease. N Engl J Med 2000;343:1148-55.
16. 2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302-6.
17. 2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-42.
18. Winkler K, Abletshauser C, Friedrich I, et al. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolaseactivity: A placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 2004;89:1153-9.
19. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: Results from the 14-year followup of a large cohort from southern Germany (MONICA-Augsburg). Circulation 2004;110:1903-8.
20. 2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation 2005;111:570-5.
21. 2 as a risk factor for coronary vascular disease in the elderly (PROSPER). Proceedings from the XIV International Symposium on Atherosclerosis; June 18-22, 2006; Rome, Italy. Abstract page 484.
22. Jenny NS, Solomon C, Cushman M, et al. Lipoprotein-associated phospholipase A2 and cardiovascular disease: Results from the Cardiovascular Health Study. Circulation 2006;113:E332. (Abst)
23. 2) independently predicts incident coronary heart disease (CHD) in an apparently healthy older population: The Rancho Bernardo Study. Circulation 2006;114:II-870. (Abst)
24. Persson M, Hedblad B, Nelson JJ, Berglund G. MALMO elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007;27:1411-6.
25. 2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007;28:699-704.
26. 2 and myocardial infarction in women. Circulation 2007;116:II-818:(A3605). (Abst)
27. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: Results of a cross-sectional analysis. J Lipid Res 2003;44:1381-6.
28. 2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26:137-44.
29. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. Circulation 2005;111:980-7.
30. Khuseyinova N, Imhof A, Rothenbacher D, et al. Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis (HELICOR). Atherosclerosis 2005;182:181-8.
31. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Arterioscler Thromb Vasc Biol 2006;26:1586-93.
32. 2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006;152:997-1003.
33. 2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006;52:1331-8.
34. Gerber Y, McConnell JP, Jaffe AS, et al. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006;26:2517-22.
35. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
36. Robins SJ, Collins D, Nelson JJ, et al. Cardiovascular events with increased lipoprotein-associated phospholipase A2 and low highdensity lipoprotein-cholesterol. The Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2008;28:1172-8.
37. Mockel M, Muller R, Vollert JO, et al. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: A multi-marker approach: The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 2007;96:604-12.
38. Sabatine MS, Morrow DA, O'Donoghue M, et al; PEACE Investigators. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2463-9.
39. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoproteinassociated phospholipase A2, high sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479-84.
40. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006;166:2073-80.
41. Robins SJ, Collins D, Nelson JJ, et al. Lipoprotein-associated phospholipase A2 predicts cardiovascular events in the low HDL-C and low LDL-C population of the Veterans Affairs HDL Intervention Trial (VA-HIT). The 2006 European Society ofCardiology World Congress of Cardiology. Barcelona, Spain, September 2006, Abstract 3448.
42. Furie KL, Parides MK, Greer DM, et al. Lipoprotein-associated phospholipase A2 activity predicts early stroke recurrence. Stroke 2007;38:458. (Abst)
43. Wassertheil-Smoller S, Kooperberg C, McGinn AP, et al. Lipoprotein-associated phospholipase A2 and risk of ischemic stroke in postmenopausal women: the Women's Health Initiative Observational Study. Circulation 2007;115:e222. (Abst)
44. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101(Suppl):51F-57F.
45. Mohler ER 3rd, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebocontrolled study. J Am Coll Cardiol 2008;51:1632-41.
46. 2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82.